Brief: Moberg Pharma Q2 Loss Widens To SEK 3.9 Mln
Aug 9 (Reuters) - Moberg Pharma AB (publ) MBPH.ST :
* INTERIM REPORT JANUARY - JUNE 2022
* Q2 EBITDA LOSS SEK 4.3 MILLION VERSUS LOSS SEK 3.5 MILLION
YEAR
AGO
* Q2 LOSS AFTER TAX SEK 3.9 MILLION VERSUS LOSS SEK 3.3
MILLION
YEAR AGO
Source text for Eikon: ID:nWkr2dbHtt
Further company coverage: MBPH.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Moberg Pharma AB (publ)
See all newsSweden's Moberg Pharma Q2 loss narrows as revenue rises
Brief: Moberg Pharma Q2 EBITDA SEK -4.3 Million
Brief: Moberg Pharma Names Vaidrius Navikas Chief Medical Officer
Brief: Moberg Pharma And Karo Healthcare Expand Collaboration
Moberg Pharma Q1 revenue rises, losses narrow on Nordic market share gains